N. B. Nyshchuk-Oliinyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
N. B. Nyshchuk-Oliinyk has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Serhii Herashchenko
Івано-Франківський національний медичний університет
5 shared publications - Mykyta Bielinskyi
Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
4 shared publications - Sergiy Fedorov
Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
3 shared publications - O. O. Tkachuk-Hryhorchuk
Івано-Франківський національний медичний університет, Україна
2 shared publications - Oksana Didushko
Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
2 shared publications - A. Y. Pavliskyi1 shared publication
Latest Publications
- Open Access
- 30 September 2026
- Published by Scientific Society Anatomists, Histologists, and Embryologists, Ukraine in World of Medicine and Biology
- Vol. 22 (97) , 130-134
ЕФЕКТИВНІСТЬ ТРОМБОЦИТАРНОГО ФІБРИНУ ПРИ ОРАЛЬНИХ УРАЖЕННЯХ У ПАЦІЄНТІВ ІЗ ВУЛЬГАРНОЮ ПУХИРЧАТКОЮ
Стійкі оральні ураження при вульгарній пухирчатці спричиняють біль, утруднюють харчування та можуть повільно загоюватися попри системне лікування. До ретроспективного порівняльного дослідження включено 58 пацієнтів, яких лікували у 2019–2024 роках: 27 додатково до стандартної системної терапії отримували тромбоцитарний фібрин, а 31 – лише стандартну терапію. Оцінювали інтенсивність і площу оральних уражень, біль за візуальною аналоговою шкалою та час до повної епітелізації. Середнє зниження показника інтенсивності становило 9,4 та 4,3 бала, показника площі – 8,6 та 3,8 бала, болю – 4,8 та 2,6 бала відповідно; для всіх міжгрупових порівнянь p
- 30 September 2026
- Published by Scientific Society Anatomists, Histologists, and Embryologists, Ukraine in World of Medicine and Biology
- Vol. 22 (97) , 130-134
Open AccessЕФЕКТИВНІСТЬ ТРОМБОЦИТАРНОГО ФІБРИНУ ПРИ ОРАЛЬНИХ УРАЖЕННЯХ У ПАЦІЄНТІВ ІЗ ВУЛЬГАРНОЮ ПУХИРЧАТКОЮ
Стійкі оральні ураження при вульгарній пухирчатці спричиняють біль, утруднюють харчування та можуть повільно загоюватися попри системне лікування. До ретроспективного порівняльного дослідження включено 58 пацієнтів, яких лікували у 2019–2024 роках: 27 додатково до стандартної системної терапії отримували тромбоцитарний фібрин, а 31 – лише стандартну терапію. Оцінювали інтенсивність і площу оральних уражень, біль за візуальною аналоговою шкалою та час до повної епітелізації. Середнє зниження показника інтенсивності становило 9,4 та 4,3 бала, показника площі – 8,6 та 3,8 бала, болю – 4,8 та 2,6 бала відповідно; для всіх міжгрупових порівнянь p
- Open Access
- 30 June 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 26-33
Adjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery
Survivors of differentiated thyroid cancer after total thyroidectomy form a growing population with increased long-term cardiovascular risk related to chronic thyroid hormone imbalance and lifelong L-thyroxine replacement. In this setting, hypothyroid cardiomyopathy with preserved left ventricular ejection fraction is associated with elevated N-terminal fragment of pro-B-type natriuretic pept ide (NT-proBNP), diastolic dysfunction, atrial remodeling and endothelial impairment. Data on disease-modifying treatment for this endocrine-driven heart failure with preserved ejection fraction (HFpEF)-like phenotype remain limited. Objective — to assess the effect of adding empagliflozin to standard beta-blocker and angiotensin-converting enzyme inhibitor therapy on left ventricular diastolic function, endothelial function and galectin-3 levels in post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction. Materials and methods. This prospective controlled study included 61 adults (57,2±7,3 years, 48 female, 23 male) after total thyroidectomy for thyroid cancer with heart failure symptoms, elevated NT-proBNP and left ventricular ejection fraction ≥50%. Patients received either standard therapy or standard therapy plus empagliflozin 10 mg/day for 6 months. Results. Baseline clinical characteristics, thyroid status, L-thyroxine dose and NT-proBNP levels were comparable between groups. Standard therapy alone produced only modest improvement in diastolic indices, flow-mediated dilation (FMD), galectin-3 and NT-proBNP. In contrast, empagliflozin was associated with greater reductions in E/e′, larger increases in e′ velocities, a more pronounced decrease in left atrial volume index, stronger improvement in FMD, and greater declines in galectin-3 and NT-proBNP. In multivariable linear mixed-effects models, time × treatment interactions for E/e′ FMD, galectin-3 and NT-proBNP remained significant. Empagliflozin was well tolerated, with no serious drug-related adverse events. Conclusions. In post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction, empagliflozin added to standard therapy was associated with greater improvement in diastolic and endothelial function and with larger reductions in galectin-3 and NT-proBNP than standard treatment alone. These findings support its potential cardio- and vasculoprotective role in endocrine-driven HFpEF phenotypes and justify larger randomized trials.
- 30 June 2026
- Published by Publishing Company VIT-A-POL in Clinical endocrinology and endocrine surgery
- No. 2,p. 26-33
Open AccessAdjunctive empagliflozin therapy in endocrine-driven heart failure with preserved ejection fraction after thyroid cancer surgery
Survivors of differentiated thyroid cancer after total thyroidectomy form a growing population with increased long-term cardiovascular risk related to chronic thyroid hormone imbalance and lifelong L-thyroxine replacement. In this setting, hypothyroid cardiomyopathy with preserved left ventricular ejection fraction is associated with elevated N-terminal fragment of pro-B-type natriuretic pept ide (NT-proBNP), diastolic dysfunction, atrial remodeling and endothelial impairment. Data on disease-modifying treatment for this endocrine-driven heart failure with preserved ejection fraction (HFpEF)-like phenotype remain limited. Objective — to assess the effect of adding empagliflozin to standard beta-blocker and angiotensin-converting enzyme inhibitor therapy on left ventricular diastolic function, endothelial function and galectin-3 levels in post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction. Materials and methods. This prospective controlled study included 61 adults (57,2±7,3 years, 48 female, 23 male) after total thyroidectomy for thyroid cancer with heart failure symptoms, elevated NT-proBNP and left ventricular ejection fraction ≥50%. Patients received either standard therapy or standard therapy plus empagliflozin 10 mg/day for 6 months. Results. Baseline clinical characteristics, thyroid status, L-thyroxine dose and NT-proBNP levels were comparable between groups. Standard therapy alone produced only modest improvement in diastolic indices, flow-mediated dilation (FMD), galectin-3 and NT-proBNP. In contrast, empagliflozin was associated with greater reductions in E/e′, larger increases in e′ velocities, a more pronounced decrease in left atrial volume index, stronger improvement in FMD, and greater declines in galectin-3 and NT-proBNP. In multivariable linear mixed-effects models, time × treatment interactions for E/e′ FMD, galectin-3 and NT-proBNP remained significant. Empagliflozin was well tolerated, with no serious drug-related adverse events. Conclusions. In post-thyroidectomy thyroid cancer patients with hypothyroid cardiomyopathy and preserved ejection fraction, empagliflozin added to standard therapy was associated with greater improvement in diastolic and endothelial function and with larger reductions in galectin-3 and NT-proBNP than standard treatment alone. These findings support its potential cardio- and vasculoprotective role in endocrine-driven HFpEF phenotypes and justify larger randomized trials.
- Open Access
- 12 June 2024
- Published by Publishing House Zaslavsky in GASTROENTEROLOGY
- Vol. 58 (2) , 102-108
Synergistic effects of ursodeoxycholic acid, and quercetin on liver function and systemic inflammation in non-alcoholic fatty liver disease and atrial fibrillation patients
Background. Non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) co-occur with significant clinical implications, necessitating therapeutic strategies that address the multifaceted nature of these conditions. This study evaluated the efficacy of standard treatment alone versus combined treatments with ursodeoxycholic acid (UDCA) and quercetin in patients with NAFLD and AF, focusing on improvements in liver function, lipid profile, systemic inflammation, and fibrosis markers. Aim: to evaluate and compare the efficacy of standard treatment alone versus standard treatment combined with ursodeoxycholic acid with and without quercetin in patients with non-alcoholic fatty liver disease and concurrent atrial fibrillation. Materials and methods. In a prospective, randomized, controlled trial, 127 patients with diagnosed NAFLD and concurrent AF were enrolled. They were divided into three groups: group 1 — standard treatment (n = 42), group 2 — standard treatment plus UDCA (n = 44), and group 3 — standard treatment plus UDCA and quercetin (n = 41). The primary outcomes included changes in liver function tests (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase, alkaline phosphatase), lipid profile (total cholesterol, low- and high-density lipoprotein cholesterol (HDL-C), triglycerides), and non-invasive liver fibrosis scores (NFS, FIB-4). Secondary outcomes focused on systemic inflammation markers (C-reactive protein, galectin-3, soluble ST2) and fibronectin levels. Results. All treatment groups showed significant improvements in liver function tests and lipid profiles. Group 3 exhibited the most substantial reductions in ALT, AST, and improvements in HDL-C, indicating enhanced hepatoprotective and lipid-modulating effects. Systemic inflammation markers and fibronectin levels decreased significantly in groups receiving UDCA and quercetin, with the most pronounced effects observed in group 3, suggesting potent anti-inflammatory and anti-fibrotic action. Additionally, significant improvements in NFS and FIB-4 scores in group 3 highlight the anti-fibrotic potential of combining UDCA and quercetin with standard treatment. Conclusions. The addition of UDCA and quercetin to standard treatment for patients with NAFLD and AF significantly improves liver function, lipid metabolism, and reduces systemic inflammation and fibrosis, compared to standard treatment alone. These findings suggest a synergistic effect of UDCA and quercetin, offering a promising therapeutic strategy for managing the complex interplay between NAFLD and AF.
- 12 June 2024
- Published by Publishing House Zaslavsky in GASTROENTEROLOGY
- Vol. 58 (2) , 102-108
Open AccessSynergistic effects of ursodeoxycholic acid, and quercetin on liver function and systemic inflammation in non-alcoholic fatty liver disease and atrial fibrillation patients
Background. Non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) co-occur with significant clinical implications, necessitating therapeutic strategies that address the multifaceted nature of these conditions. This study evaluated the efficacy of standard treatment alone versus combined treatments with ursodeoxycholic acid (UDCA) and quercetin in patients with NAFLD and AF, focusing on improvements in liver function, lipid profile, systemic inflammation, and fibrosis markers. Aim: to evaluate and compare the efficacy of standard treatment alone versus standard treatment combined with ursodeoxycholic acid with and without quercetin in patients with non-alcoholic fatty liver disease and concurrent atrial fibrillation. Materials and methods. In a prospective, randomized, controlled trial, 127 patients with diagnosed NAFLD and concurrent AF were enrolled. They were divided into three groups: group 1 — standard treatment (n = 42), group 2 — standard treatment plus UDCA (n = 44), and group 3 — standard treatment plus UDCA and quercetin (n = 41). The primary outcomes included changes in liver function tests (alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase, alkaline phosphatase), lipid profile (total cholesterol, low- and high-density lipoprotein cholesterol (HDL-C), triglycerides), and non-invasive liver fibrosis scores (NFS, FIB-4). Secondary outcomes focused on systemic inflammation markers (C-reactive protein, galectin-3, soluble ST2) and fibronectin levels. Results. All treatment groups showed significant improvements in liver function tests and lipid profiles. Group 3 exhibited the most substantial reductions in ALT, AST, and improvements in HDL-C, indicating enhanced hepatoprotective and lipid-modulating effects. Systemic inflammation markers and fibronectin levels decreased significantly in groups receiving UDCA and quercetin, with the most pronounced effects observed in group 3, suggesting potent anti-inflammatory and anti-fibrotic action. Additionally, significant improvements in NFS and FIB-4 scores in group 3 highlight the anti-fibrotic potential of combining UDCA and quercetin with standard treatment. Conclusions. The addition of UDCA and quercetin to standard treatment for patients with NAFLD and AF significantly improves liver function, lipid metabolism, and reduces systemic inflammation and fibrosis, compared to standard treatment alone. These findings suggest a synergistic effect of UDCA and quercetin, offering a promising therapeutic strategy for managing the complex interplay between NAFLD and AF.
- Open Access
- 30 May 2024
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 20 (3) , 173-178
Enhanced therapy for coronary artery disease and diabetes mellitus: impact on biomarkers and clinical outcomes
Background. Cardiovascular diseases like coronary artery disease (CAD) are a major global health issue, causing millions of deaths each year. Type 2 diabetes mellitus (T2DM) worsens outcomes for those with CAD. Common risk factors suggest potential synergistic treatment approaches, including the use of quercetin, a natural flavonoid. The purpose was to examine the clinical efficacy and safety of empagliflozin and quercetin in the treatment of coronary artery disease and type 2 diabetes mellitus comorbidity in the light of their impact on parameters of inflammation. Materials and methods. A total of 128 patients diagnosed with both stable CAD and T2DM were enrolled in the study between January and December 2023. Participants were categorized into three groups. Group 1 (controls): 40 patients receiving the standard treatment protocol for CAD and T2DM. Group 2: 46 patients received standard therapy in addition to empagliflozin (10 mg daily). Group 3: 42 patients received standard therapy in addition to empagliflozin (10 mg daily) and quercetin (80 mg three times a day). Results. The results showed that age and gender were similar between the groups, indicating a balanced distribution. The study then evaluated the effects of treatment on various parameters. The baseline body mass index (BMI), glucose, glycated hemoglobin (HbA1c), soluble suppression of tumorigenicity 2 (sST2), Toll-like receptor 2 (TLR2) and TLR4 levels were comparable across all groups. After treatment, significant reductions were observed in BMI, fasting glucose, HbA1c, sST2, and TLR2/TLR4 in all groups. The most significant improvements were seen in the group that received both empagliflozin and quercetin. The findings highlight the potential benefits of these interventions in patients with coronary heart disease and type 2 diabetes mellitus. Conclusions. The addition of empagliflozin and quercetin to standard therapy appears to offer significant benefits in managing BMI, glycemic control, and inflammatory markers in patients with CAD and T2DM. The combined treatment regimen has potential to address the complex interplay of metabolic and inflammatory processes in high-risk patients. The proposed combination also showed efficacy in reducing the myocardial stress, which is shown by a decrease in serum sST2.
- 30 May 2024
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 20 (3) , 173-178
Open AccessEnhanced therapy for coronary artery disease and diabetes mellitus: impact on biomarkers and clinical outcomes
Background. Cardiovascular diseases like coronary artery disease (CAD) are a major global health issue, causing millions of deaths each year. Type 2 diabetes mellitus (T2DM) worsens outcomes for those with CAD. Common risk factors suggest potential synergistic treatment approaches, including the use of quercetin, a natural flavonoid. The purpose was to examine the clinical efficacy and safety of empagliflozin and quercetin in the treatment of coronary artery disease and type 2 diabetes mellitus comorbidity in the light of their impact on parameters of inflammation. Materials and methods. A total of 128 patients diagnosed with both stable CAD and T2DM were enrolled in the study between January and December 2023. Participants were categorized into three groups. Group 1 (controls): 40 patients receiving the standard treatment protocol for CAD and T2DM. Group 2: 46 patients received standard therapy in addition to empagliflozin (10 mg daily). Group 3: 42 patients received standard therapy in addition to empagliflozin (10 mg daily) and quercetin (80 mg three times a day). Results. The results showed that age and gender were similar between the groups, indicating a balanced distribution. The study then evaluated the effects of treatment on various parameters. The baseline body mass index (BMI), glucose, glycated hemoglobin (HbA1c), soluble suppression of tumorigenicity 2 (sST2), Toll-like receptor 2 (TLR2) and TLR4 levels were comparable across all groups. After treatment, significant reductions were observed in BMI, fasting glucose, HbA1c, sST2, and TLR2/TLR4 in all groups. The most significant improvements were seen in the group that received both empagliflozin and quercetin. The findings highlight the potential benefits of these interventions in patients with coronary heart disease and type 2 diabetes mellitus. Conclusions. The addition of empagliflozin and quercetin to standard therapy appears to offer significant benefits in managing BMI, glycemic control, and inflammatory markers in patients with CAD and T2DM. The combined treatment regimen has potential to address the complex interplay of metabolic and inflammatory processes in high-risk patients. The proposed combination also showed efficacy in reducing the myocardial stress, which is shown by a decrease in serum sST2.
- Open Access
- 1 January 2024
- Published by Publishing House Helvetica (Publications)
- No. 5,p. 24-30
IMPACT OF BEDTIME ANTIHYPERTENSIVE MEDICATION AND SLEEP QUALITY ENHANCEMENT ON NON-DIPPER HYPERTENSION
Non-dipper hypertension characterized by a lack of nocturnal blood pressure reduction is associated with adverse cardiovascular outcomes and poor sleep quality. The objective of the study is to evaluate efficacy of bedtime administration of antihypertensive drugs and the pharmacological treatment of the sleep quality. Materials and methods. The study was conducted at Ivano-Frankivsk National Medical University, involving 65 patients divided into three groups. Group 1 (n=18) received a fixed combination of perindopril (8 mg) and indapamide (2.5 mg) in the morning. Group 2 (n=25) received the same medication in the evening. Group 3 (n=22) received the medication plus a combination of L-tryptophan and vitamins (Pineal-Tens) in the evening. Patients were monitored for three months using ambulatory blood pressure monitoring (Cardiosense BP) and arterial stiffness assessment (Siemens NX3 Elite ultrasound). Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Statistical analysis included Kruskal-Wallis, Chi-square, and Bonferroni tests. Results. Baseline characteristics were well-matched across groups. Post-treatment, Groups 2 and 3 showed significant reductions in nighttime systolic and diastolic blood pressure compared to Group 1. Group 3 exhibited significant improvements in subjective sleep quality, sleep duration, and habitual sleep efficiency. The proportion of non-dippers significantly decreased in Groups 2 and 3, indicating better circadian blood pressure regulation. Arterial stiffness, measured by pulse wave velocity, significantly improved in Groups 2 and 3. Conclusions: Evening administration of antihypertensive drugs significantly reduces nighttime blood pressure. The combination therapy with L-tryptophan and vitamins significantly improves sleep quality. Bedtime administration helps restore normal circadian blood pressure patterns and reduces arterial stiffness. Стаття присвячена оцінці ефективності вечірнього прийому антигіпертензивних препаратів та фармакологічного покращення якості сну у пацієнтів з гіпертензією профілю нон-діппер. У дослідженні взяли участь 65 пацієнтів, що були розділені на три групи. Група 1 отримувала периндоприл та індапамід вранці, група 2 – ввечері, а група 3 – ввечері разом з L-триптофаном і вітамінами (Пінеал-Тенс). Результати показали значне зниження нічного систолічного і діастолічного артеріального тиску у групах 2 і 3 порівняно з групою 1. Значні покращення у якості сну були відзначені у групі 3, включаючи збільшення тривалості сну та ефективності сну. Вечірній прийом антигіпертензивних препаратів допомагає нормалізувати циркадний ритм артеріального тиску та зменшує жорсткість артерій, що сприяє покращенню загального стану здоров’я пацієнтів.
- 1 January 2024
- Published by Publishing House Helvetica (Publications)
- No. 5,p. 24-30
Open AccessIMPACT OF BEDTIME ANTIHYPERTENSIVE MEDICATION AND SLEEP QUALITY ENHANCEMENT ON NON-DIPPER HYPERTENSION
Non-dipper hypertension characterized by a lack of nocturnal blood pressure reduction is associated with adverse cardiovascular outcomes and poor sleep quality. The objective of the study is to evaluate efficacy of bedtime administration of antihypertensive drugs and the pharmacological treatment of the sleep quality. Materials and methods. The study was conducted at Ivano-Frankivsk National Medical University, involving 65 patients divided into three groups. Group 1 (n=18) received a fixed combination of perindopril (8 mg) and indapamide (2.5 mg) in the morning. Group 2 (n=25) received the same medication in the evening. Group 3 (n=22) received the medication plus a combination of L-tryptophan and vitamins (Pineal-Tens) in the evening. Patients were monitored for three months using ambulatory blood pressure monitoring (Cardiosense BP) and arterial stiffness assessment (Siemens NX3 Elite ultrasound). Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). Statistical analysis included Kruskal-Wallis, Chi-square, and Bonferroni tests. Results. Baseline characteristics were well-matched across groups. Post-treatment, Groups 2 and 3 showed significant reductions in nighttime systolic and diastolic blood pressure compared to Group 1. Group 3 exhibited significant improvements in subjective sleep quality, sleep duration, and habitual sleep efficiency. The proportion of non-dippers significantly decreased in Groups 2 and 3, indicating better circadian blood pressure regulation. Arterial stiffness, measured by pulse wave velocity, significantly improved in Groups 2 and 3. Conclusions: Evening administration of antihypertensive drugs significantly reduces nighttime blood pressure. The combination therapy with L-tryptophan and vitamins significantly improves sleep quality. Bedtime administration helps restore normal circadian blood pressure patterns and reduces arterial stiffness. Стаття присвячена оцінці ефективності вечірнього прийому антигіпертензивних препаратів та фармакологічного покращення якості сну у пацієнтів з гіпертензією профілю нон-діппер. У дослідженні взяли участь 65 пацієнтів, що були розділені на три групи. Група 1 отримувала периндоприл та індапамід вранці, група 2 – ввечері, а група 3 – ввечері разом з L-триптофаном і вітамінами (Пінеал-Тенс). Результати показали значне зниження нічного систолічного і діастолічного артеріального тиску у групах 2 і 3 порівняно з групою 1. Значні покращення у якості сну були відзначені у групі 3, включаючи збільшення тривалості сну та ефективності сну. Вечірній прийом антигіпертензивних препаратів допомагає нормалізувати циркадний ритм артеріального тиску та зменшує жорсткість артерій, що сприяє покращенню загального стану здоров’я пацієнтів.
- Open Access
- 29 December 2023
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 19 (8) , 559-565
Impact of type 2 diabetes mellitus on heart failure with preserved ejection fraction depending on the presence of atrial fibrillation
Background. Cardiovascular diseases, including heart failure (HF) and heart failure with preserved ejection fraction (HFpEF), pose a global health challenge. HFpEF is on the rise, especially among the elderly and those with conditions like diabetes, obesity, and hypertension. Type 2 diabetes mellitus (T2DM) often coexists with HFpEF, and atrial fibrillation (AF) further complicates matters due to shared risk factors. The purpose of this study is to comprehensively investigate the influence of type 2 diabetes mellitus on cardiac function and biomarker profiles in patients with heart failure with preserved ejection fraction in the presence or absence of atrial fibrillation. Materials and methods. This was a cohort, single-center study. Four hundred and forty-eight patients with HFpEF were examined. They were divided into 4 groups: group 1 — 189 patients with HFpEF alone; group 2 — 39 patients with HFpEF and T2DM; group 3 — 176 patients with HFpEF and atrial fibrillation; group 4 — 44 patients with HFpEF, AF, T2DM. Results. T2DM may contribute to a slightly older patient population in HFpEF, but age alone is not a primary discriminator. T2DM alone does not substantially impact left ventricular mass index but, when combined with AF, it does. T2DM is associated with an increased left atrial volume index, and AF intensifies this effect. T2DM influences diastolic function, with AF exacerbating it. T2DM affects left ventricular filling pressure, and AF worsens this in HFpEF. T2DM also influences left ventricular systolic function, further compromised when combined with AF in HFpEF patients. Galectin-3 levels are elevated in HFpEF patients with T2DM, further exacerbated with AF. NT-proBNP levels are influenced by T2DM and worsened with the combination of AF in HFpEF. SST2 levels are elevated in HFpEF patients with T2DM, further increased with AF, indicating myocardial fibrosis and adverse remodeling. Conclusions. The interaction between T2DM and AF in HFpEF patients creates a synergistic effect, resulting in significant cardiac structural and functional alterations. Novel biomarkers such as galectin-3, NT-proBNP, and sST2 emerge as valuable diagnostic tools, reflecting the complex pathophysiological processes in HFpEF.
- 29 December 2023
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 19 (8) , 559-565
Open AccessImpact of type 2 diabetes mellitus on heart failure with preserved ejection fraction depending on the presence of atrial fibrillation
Background. Cardiovascular diseases, including heart failure (HF) and heart failure with preserved ejection fraction (HFpEF), pose a global health challenge. HFpEF is on the rise, especially among the elderly and those with conditions like diabetes, obesity, and hypertension. Type 2 diabetes mellitus (T2DM) often coexists with HFpEF, and atrial fibrillation (AF) further complicates matters due to shared risk factors. The purpose of this study is to comprehensively investigate the influence of type 2 diabetes mellitus on cardiac function and biomarker profiles in patients with heart failure with preserved ejection fraction in the presence or absence of atrial fibrillation. Materials and methods. This was a cohort, single-center study. Four hundred and forty-eight patients with HFpEF were examined. They were divided into 4 groups: group 1 — 189 patients with HFpEF alone; group 2 — 39 patients with HFpEF and T2DM; group 3 — 176 patients with HFpEF and atrial fibrillation; group 4 — 44 patients with HFpEF, AF, T2DM. Results. T2DM may contribute to a slightly older patient population in HFpEF, but age alone is not a primary discriminator. T2DM alone does not substantially impact left ventricular mass index but, when combined with AF, it does. T2DM is associated with an increased left atrial volume index, and AF intensifies this effect. T2DM influences diastolic function, with AF exacerbating it. T2DM affects left ventricular filling pressure, and AF worsens this in HFpEF. T2DM also influences left ventricular systolic function, further compromised when combined with AF in HFpEF patients. Galectin-3 levels are elevated in HFpEF patients with T2DM, further exacerbated with AF. NT-proBNP levels are influenced by T2DM and worsened with the combination of AF in HFpEF. SST2 levels are elevated in HFpEF patients with T2DM, further increased with AF, indicating myocardial fibrosis and adverse remodeling. Conclusions. The interaction between T2DM and AF in HFpEF patients creates a synergistic effect, resulting in significant cardiac structural and functional alterations. Novel biomarkers such as galectin-3, NT-proBNP, and sST2 emerge as valuable diagnostic tools, reflecting the complex pathophysiological processes in HFpEF.